**Name of journal: World Journal of Hepatology**

**ESPS Manuscript NO: 6134**

**Columns: REVIEW**

**Life cycle and pathogenesis of hepatitis D virus: A review**

Abbas Z *et al.* Pathogenesis of hepatitis D virus

Zaigham Abbas, Rafia Afzal

**Zaigham Abbas, Rafia Afzal,** Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi 75500, Pakistan

**Author contributions:** Abbas Z designed the review’s objectives; Afzal Z searched the literature for latest developments in the field; all authors were involved in reviewing the literature, writing and editing the manuscript.

**Correspondence to: Dr. Zaigham Abbas,** Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi 75500, Pakistan. drzabbas@gmail.com

**Telephone:** +92-21-32728998 **Fax:** +92-21-32728998

**Received:** October 3, 2013  **Revised:** November 6, 2013

**Accepted:** November 15, 2013

**Published online:**

#### Abstract

#### Hepatitis D virus (HDV) is a defective RNA virus, which requires the help of hepatitis B (HBV) virus for its replication and assembly of new virions. HDV genome contains only one actively transcribed open reading frame which encodes for two isoforms of hepatitis delta antigen. Post-translational modifications of small and large delta antigens (S-HDAg and L-HDAg) involving phosphorylation and isoprenylation respectively confer these antigens their specific properties. S-HDAg is required for the initiation of the viral genome replication, whereas L-HDAg serves as a principal inhibitor of replication and is essential for the assembly of new virion particles. Immune mediation has usually been implicated in HDV-associated liver damage. The pathogenesis of HDV mainly involves interferon-α signaling inhibition, HDV-specific T-lymphocyte activation and cytokine responses, and tumor necrosis factor-alpha and nuclear factor kappa B signaling. Due to limited protein coding capacity, HDV makes use of host cellular proteins to accomplish their life cycle processes including transcription and replication; post-transcriptional and translational modifications. This intimate host-pathogen interaction significantly alters cell proteome and is associated with an augmented expression of pro-inflammatory, growth and anti-apoptotic factors which explains severe necro-inflammation and increased cell survival and an early progression to hepatocellular carcinoma in HDV patients. The understanding of the process of viral replication, HBV-HDV interactions, and etio-pathogenesis of the severe course of HDV infection is helpful in identifying the potential therapeutic targets in the virus life cycle for the prophylaxis and treatment of HDV infection and complications.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Hepatitis B virus; Hepatitis D virus; Hepatitis delta antigens; Virus replication; Host-pathogen interactions; Hepatitis D virus pathogenicity; Interferon-alpha; Hepatocellular carcinoma

**Core tip:** A scarcity of literature over hepatitis D virus (HDV) life cycle and pathogenesis is clearly evident. Severity of HDV associated liver disease and lack of an efficient treatment regime therefore warrant urgent research into HDV biology. Virus entry inhibitors and isoprenylation inhibitors may play a role in preventing HDV superinfection and liver cirrhosis. As inhibition of interferon-α signaling by HDV plays a pivotal role in failure to clear the virus, testing interferon-free treatment regimens should undergo clinical trials. A low degree of heterogeneity in hepatitis delta antigen encourages the development of a vaccine using its immunogenic sequences.

Abbas Z, Afzal R. Life cycle and pathogenesis of hepatitis D virus: A review

**Available from:**

**DOI:**

**INTRODUCTION**

The smallest virus known to infect humans, hepatitis delta virus (HDV), is increasingly becoming again a cause of fulminant hepatitis or a more rapid progression of liver disease in the setting of chronic hepatitis B virus (HBV) infection[1]. HDV is a defective satellite RNA virus, which requires the helper function of HBV for its replication and assembly of new virions[2]. An estimated 15-20 million individuals with HBV worldwide are found infected with HDV[2], highlighting a need to exactly understand the pathogenesis and molecular biology of the virus.

**GENOMIC STRUCTURE AND TAXONOMIC CLASSIFICATION**

HDV is a small, spherical virus with a diameter of about 36 nm[1,3]. The viral genome is a circular, single-stranded, negative sense RNA molecule with an internal core delta antigen surrounded by an envelope derived from HBV surface proteins[4,5]. The genomic RNA of HDV composed of approximately 1700 nucleotides, packaged with about 200 molecules of hepatitis delta antigen (HDAg)[6] to form a single viral particle. Due to extensive base-pairing within the RNA molecule, the genome appears double-stranded rod like structure and thus it resembles viroids (plant pathogens) remarkably[1,7]. However, unlike viroids, the HDV has more number of nucleotides in its genome as compared to 200-400 nucleotides in a viroid RNA. Furthermore, viroids lack protein coding ability whereas HDV codes for its own hepatitis delta antigen (HDAg) and requires HBV for its propagation[7]. The envelope surrounds the genome and HDAg composed of all three HBV envelope proteins, namely; small hepatitis B surface antigen (S-HBsAg), medium HBsAg and large HBsAg. The HDV genome also exhibits a self-cleavage activity by encoding a ribozyme domain about 80-100 nucleotides long. HDV seems to be a unique animal virus because of its high GC nucleotide content and circle rolling mechanism of replication[8-10]. The virus is currently assigned the separate genus Deltavirus, and yet awaits a complete taxonomic classification including order and family.

Unlike most RNA viruses, HDV does not encode its own replicase or RNA- dependant RNA polymerase to replicate its genome, rather it makes use of cellular RNA polymerases which are DNA-dependant RNA polymerases. Since HDV genomic RNA has negative or anti-messenger polarity, during replication three different forms of RNA are being made; circular genomic RNA, circular complementary anti-genomic RNA and a linear anti-genomic RNA through circle rolling mechanism. The circle rolling mechanism involves unidirectional replication of nucleic acids to form multiple copies of circular genome using cellular RNA polymerases[11]. Linear polyadenylated anti-genomic RNA serves as messenger RNA (mRNA) to produce HDAg.

Since HDV is presented with a limited protein coding capacity encoding only one HDAg having two isoforms, it thus makes use of host cellular machinery (cellular proteins) to accomplish the processes which are essential for its life cycle such as; transcription, replication, post-transcriptional and translational modifications[9,12].

**HDV ANTIGEN**

HDV genome has been found to contain several open reading frames (ORFs)[13]. Out of all the open reading frames, only one appears to be actively transcribed and encodes for antigen (HDAg)[5], the function of the rest of the ORFs is still unknown. There are two isoforms of HDAg; small HDAg 24kDa (S-HDAg) composed of 195 amino acids and large HDAg 27kDa comprising of 214 amino acids (L-HDAg). The open reading frame transcribes into a mRNA using host cell RNA polymerase II which translates to produce S-HDAg. A post-transcriptional modification by the cellular enzyme adenosine deaminase-1 (ADAR 1) replaces the stop codon (UAG at position 196) on the mRNA by a tryptophan (codon UGG), extending the reading frame by an additional 19 amino acids leading to the production of L-HDAg[5,11,14].The nineteen extra amino acids added at the carboxyl terminal of L-HDAg confer it functional properties that are different from S-HDAg. S-HDAg is required for the initiation of the viral genome replication, whereas L-HDAg which is synthesized in the late stage of viral replication serves as a principal inhibitor of replication and is essential for the assembly of new virion particles[8,9]. L-HDAg not only regulates HDV genome replication but also its own synthesis by inhibiting viral replication which prevents editing of amber/W site necessary for the expression of L-HDAg[15].

The HDAg contains different functional domains as; RNA-binding domain, coiled-coil sequence, nuclear localization sequence. The L-HDAg in addition contains few more domains which include virus assembly signal (VAS) and nuclear export signal[8,9]. VAS in the L-HDAg renders it obligate for virion assembly[16]. HDAg may directly activate transcription of the viral genome by binding to RNA. HDAg may also facilitate transcription elongation by replacing transcription repressor bound to RNA polymerase II[8,9,16]. In the absence of HBsAg, both the S-HDAg and L-HDAg tend to localize in the nucleus as they carry nuclear localization signals. Thus, HBsAg is essential for cytoplasmic translocation of L-HDAg as only L-HDAg bears nuclear export signal for the purpose of its established role in virion assembly[17].

**POST-TRANSLATIONAL MODIFICATIONS OF HDAG**

The post-translational modifications of HDAg have been reported[8,7,18] and are of immense importance as these may modulate HDAg function and may lead to progression of the viral cycle[17]. These post-translational modifications include serine and threonine phosphorylation, lysine acetylation, arginine methylation, lysine sumoylation and cysteine farnesylation[9,12]. Since HDV is deficient in enzymes responsible for post-translational modifications, HDV precisely depends upon cellular proteins to accomplish these processes.

Phosphorylation occurs at the serine and threonine residues of S-HDAg whereas only serine residues are phosphorylated in L-HDAg[9,19].Post-translational phosphorylation of S-HDAg at serine-177 is crucial for its interaction with the cellular RNA polymerase II[20], which is responsible for genomic HDV RNA synthesis (HDV antigenome RNA replication). Phosphorylation of S-HDAg at serine-177 and also phosphorylation at serine-2 residue[21] therefore enhances HDV replication. Furthermore, RNA-binding activity of HDAg has found to be mediated by phosphorylational modification and thus seems essential for viral replication[21].

Acetylation of lysine residues of both the S-HDAg and L-HDAg have been reported and are being associated with modulation of HDV replication. Mu *et al*[22]found that a substitution of acetylated Lysine-72 of S-HDAg by an alanine re-localized the mutant S-HDAg into the cytoplasm and it was associated with the diminished viral RNA accumulation and earlier L-HDAg appearance. Methylation of the arginine residue of S-HDAg has been observed to influence HDV replication[17,18] and thus so, methylation inhibitors result in an inhibition of HDV replication.

Sumoylation is a newly known post-translational modification which involves the conjugation of S-HDAg with a small ubiquitin-related modifier isoform-1 (SUMO-1; small ubiquitin-like protein) results in sumoylation of multiple lysine residues in S-HDAg and an enhanced genomic RNA and mRNA synthesis with no effect on anti-genomic transcription[9,23].

Isoprenylation is the most important modification, which results in farnesylation of the cysteine-211 which resides in the isoprenylation signal sequence located at the carboxyl terminal of L-HDAg. Farnesylated L-HDAg inhibits viral RNA replication and facilitates virion assembly by mediating the direct binding between L-HDAg and HBV envelope proteins[9]. Farnesyl inhibitors though, yet in their early phase of development may improve disease outcome.

**CELL ATTACHMENT, ENTRY, UNCOATING AND REPLICATION**

The mechanism of entry of the HDV into the hepatocytes is not clearly understood, however, it’s thought to be similar to HBV. HDV enters hepatocytes by binding to the carbohydrate side chains of heparin sulphate proteoglycan present on the surface of hepatocytes[24]. The N-terminal aminoacids of the pre-S1 domain of L-HBsAg are thus obligatory to HDV entry into hepatocytes. Mutations/deletions in highly conserved pre-S1 sequence, and acetylation or myristylation of pre-S1 N-terminal amino acids have been found to inhibit HDV entry into hepatocytes[25].Recently, Yan *et al*[26] have identified a putative receptor for the entry of HBV and HDV into the hepatocytes. The authors proposed that pre-S1 domain of L-HBsAg interacts with sodium-taurocholate cotransporting polypeptide (NTCP), an integral transmembrane glycoprotein involved in enterohepatic circulation, to facilitate HDV infection.

After HDV enters the cell, the uncoating of viral particle occurs and HDAg translocates the viral genome into the nucleus where RNA polymerases I and II are employed to replicate the genome (Figure 1). Polymerase I involves the transcription of antigenome from viral genome in the nucleolus while polymerase II catalyzes genome replication from antigenome and transcription of mRNA in the nucleoplasm[27].

The process of replication starts with the transcription of antigenome using the viral genome through a circle rolling mechanism which produces an antigenomic RNA of more than one unit length, the antigenomic RNA is then self-cleaved by intrinsic ribozyme activity and ligated to form a circular antigenome using cellular ligases. The antigenomic RNA is then used to produce genomic RNA in the nucleoplasm. The mRNA is transcribed using the same genomic transcript and is translated to produce HDAg. It is therefore evident that HBV plays no role in HDV replication and it can proceed even in the absence of the helper virus. It is required only for cell entry, virion assembly and export.

**PATHOGENESIS**

HDV replicates only in the hepatocytes, the cellular damage associated with HDV infection thus involves mainly the liver. Immune-mediated liver damage is thought to be implicated in HDV infection[28].However, data from experimental chimpanzees has also suggested a direct cytopathic effect of HDV on hepatocytes particularly in acute hepatitis setting[29-32]. It is postulated that in acute HDV infection, infected hepatocytes undergo degenerative changes characterized by shrunken eosinophilic cytoplasm and pyknotic nuclei as well as presence of minimal inflammatory cells in the liver parenchyma, consistent with cytopathic hepatocellular damage. These findings are also evident from *in vitro* (cell culture system)[33] and human studies[34,35]. Small delta antigen expressed by infected hepatocytes is thought responsible for this direct cytopathic effect of HDV[33], while large delta antigen per se is non-cytotoxic and promotes persistence of HDV (chronicity) and makes hepatocytes susceptible to immune-mediated damage.

Experimental woodchuck models have proven very helpful in furthering our knowledge of HDV pathogenesis and the chronicity associated with HDV superinfection[36, 37], owing to the marked resemblance between the course of disease in woodchuck models and the outcome of HDV superinfection in humans. In addition, these models are also invaluable for testing the efficacy and protective role of new treatments for HDV including vaccine candidates. Studies on these experimental models have disclosed that both the protein immunization and DNA immunization for HDV are insignificant in protecting against HDV superinfection[38,39], highlighting the need of adopting different approaches to develop an HDV vaccine.

Variation in immune-mediated responses during acute and chronic HDV infection has been noticed[37,40], which may explain the persistence and chronicity of HDV superinfection. Cytotoxic T lymphocytes are mainly responsible for clearing the virus by destroying HDV-infected cells. Delayed and insufficient immune response with ability of recognizing only limited viral epitopes has been implicated in failure to clear the infection coupled with establishment of chronic infection. Fulminant hepatic failure has been observed in 1% of HBV/HDV co-infected patients while in 5% of those superinfected with HDV. An exaggerated immune response particularly cell-mediated one is proposed to be involved in causing massive hepatocyte necrosis and liver damage in fulminant hepatic failure[41,42].

The pathogenesis of HDV is also thought to be influenced by the interaction of HDV with the HBV[28,43],which has not yet been clearly elucidated by investigating bodies. HDV infection is known to occur either as a co-infection or a super-infection. A co-infection with HBV/ HDV usually eradicates both the organisms and often results in complete recovery, while a super-infection frequently progresses into chronic hepatitis D infection[44]. Patients with chronic hepatitis B who develop superinfection with hepatitis D may also go into acute on chronic liver failure leading to ascites and hepatic encephalopathy.

**HBV-HDV INTERACTION**

HBV co-infection with other hepatitis viruses is associated with various patterns of reciprocal inhibition of viral replication. HDV has been frequently shown to suppress HBV replication[45]. L-HDAg up-regulates the myxovirus resistance-A transcription, an interferon-inducible antiviral response mediator which is involved in suppression of HBV replication. It is therefore suggested that the liver disease in HBV/HDV super-infection is mainly due to HDV[8].Chronic HDV/HBV infection causes a more severe liver disease than HBV mono-infection alone, the disease runs a rapidly progressive course leading to early cirrhosis, decompensation and hepatocellular carcinoma (HCC) and a shorter 5 year survival[46].

Suppression of HBV replication by HDV is not sustained for an overall period of the disease as the viral response changes over time[47].One study revealed significant HBV replication in about half of the patients[48]. Taken together, three phases of chronic hepatitis D have been proposed: (1) early active phase with active HDV replication and suppression of HBV; (2) a second moderately active one with decreasing HDV and reactivating HBV; and (3) late phase with the development of cirrhosis and hepatocellular carcinoma caused by replication of either virus or with remission resulting from the marked reduction of both viruses[49].

**INTERFERON-ALPHA SIGNALING INHIBITION**

#### The pathogenesis of HDV mainly involves Interferon-α (IFN-α) signaling inhibition[50],HDV- specific T-lymphocyte activation and cytokine responses[51,52,53], tumor necrosis factor-alpha (TNF-α) and nuclear factor kappa B signaling[54,55], together with modifications in cell proteome and an associated increased cell survival potential[56] (Figure 2).

IFN-α signaling by the virus-infected cells to warn their neighboring cells of a viral presence is a first line of defense of the host to eradicate viruses. IFN-α is induced by the double-stranded RNA presented during viral replication[57]. The IFNs thus, produced exert their effect by binding to α and β-IFN receptors on the cell surface, resulting in activation of the tyrosine kinases of the janus kinase (JAK) family which in turn phosphorylate tyrosine residues of the cytoplasmic transcription factors acting as signal transducer and activator of transcription (STAT). Activation of JAK/STAT signaling pathway stimulates the expression of IFN-induced genes. The IFN-α-stimulated genes then code for the antiviral proteins namely; myxovirus resistance A, double-stranded RNA (dsRNA)-activated protein kinase and 2', 5'-oligoadenylate synthetase which, in turn, mount an antiviral response[58].The resultant activated non-specific innate and specific acquired immune responses help combat the viral infection. But this is not the case in the setting of HDV infection.

Since HDV is composed of a single-stranded RNA molecule, it is not expected that it would stimulate IFN-α release[59]. On the other hand, interferon-alpha signaling activation has shown to be inhibited in HDV infection[50]. HDV averts tyrosine kinase-2 (tyr-2) activation preventing phosphorylation of STAT-1 and STAT-2, and their intra-nuclear translocation for the expression of IFN-induced genes, HDV thus interferes with the activation of JAK/STAT signaling pathway by IFN-α signaling inhibition[50] which may be implicated in viral persistence and treatment failure (Figure 3).

IFN-α is also known to stimulate the cellular enzyme adenosine deaminase-1 (ADAR 1) and thus L-HDAg expression by increased editing of mRNA[60]. IFN-α signaling failure in HDV infection may prevent an early production of L-HDAg and cessation of viral replication. From the above description, it could be concluded that inhibition of IFN-α signaling in HDV infected individual plays a pivotal role in failure to clear the virus and also confers resistance to IFN-α treatment. Babiker *et al*[61] tested an interferon-sparing antiviral treatment regime consisting of tenofovir disoproxil fumarate and lamivudine in a patient with severe acute HDV infection. Successful suppression of HDV RNA was achieved after 16 mo of treatment along with significant reductions in HBV DNA and HBsAg levels. The interferon-sparing regimens should undergo more clinical trials to establish their efficacy for the treatment of hepatitis D.

**T CELL RESPONSES**

It is already established that the pathogenesis of liver injury in HDV infection is not directly cytopathic but immune-mediated mechanisms are known to involve. After the entry of virus into hepatocytes, its antigen is being processed in endoplasmic reticulum of cell cytoplasm and presented on the cell surface in association with major histocompatibility complex-I (MHC-I) protein. CD8+ cytotoxic T lymphocytes recognize endogenously synthesized antigen presented in association with class-I MHC proteins and kill the virus infected cell by two mechanisms; release of perforins and granzymes and an interaction between FAS receptor and FAS ligand. Both of these mechanisms lead to DNA fragmentation and apoptosis of the target cells[62].

Secondly, exogenous antigens and noninfectious viral particles are endocytosed by the surrounding antigen- presenting cells (APCs) (which include macrophages, B lymphocytes and dendritic cells) which present the antigens on their surface in association with class II MHC proteins. CD4+ helper T-cells recognize antigens when they are presented in association with class II MHC proteins. A virus-specific clone of helper T cells is thus activated and starts proliferating to bring about clonal expansion in order to clear the viral infection. Proliferating helper T- cells are categorized into three subtypes; type 0 (Th-0), Th-1 and Th-2 T cells on the basis of their functions and cytokines they produce. Thus, an HDV-specific activated clone of helper T-cell is the key component around which the pathogenesis of HDV revolve[52].

**CYTOKINES**

The pathogenesis of HDV involves activation of a clone of HDV- specific helper T- cell which, in turn, expresses cytokines mainly interleukin-2 (IL-2), IL-2 receptor, IL-10 and IFN-ϒ[51,52, 63]. IL-2 being, a T- cell growth and differentiation factor stimulate both HDV- specific helper T cell and CD8+ cytotoxic T cell to proliferate and undergo clonal expansion. Cytotoxic T cells destroy virus-infected cells while the activated helper T cells under the influence of IL-12 develop into subtype Th-1 cells and specifically secrete IFN-ϒ.

In HDV infection, HDV- specific Th-1 and cytotoxic T cells have been shown to produce large amount of IFN-ϒ[52] which stimulates phagocytosis and killing by macrophages and up-regulates the expression of class- I and class- II MHC proteins on cell surfaces. IFN-ϒ may inhibit viral replication directly or from its immune-modulatory and immune-stimulatory effects[51], IFN-ϒ also stimulates the secretion of IFN-ϒ induced protein-10 (CXCL-10), a chemoattractant which recruits natural killer cells (NK cells), T-cells, macrophages/monocytes and dendritic cells to destroy HDV-infected cells with the consequent viral clearance at the cost of inflammatory infiltrates causing liver damage[61].

It is also postulated that in chronic hepatitis, production of IFN-ϒ by the Th-1 helper T-cells induces hepatocytes to express class- II MHC protein in addition to class-I MHC protein in an attempt to increase their capacity to clear the infection[53]. This may be associated with severe liver necrosis and increased severity of hepatitis in HDV- infected patients as more un-infected hepatocytes expressing MHC- II protein will also be recognized and killed by helper T and cytotoxic T cells.

Since, HDV- specific CD4+ T-cell response has been identified in HDV infected patients in response to HDAg, there are specific sequences on HDAg identified which are being recognized and processed by APCs[52] and presented on the cell surface in association with MHC-II protein to mount an HDV- specific antiviral response by CD4+ helper T-cells. [R Nisini](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nisini%20R%5Bauth%5D) *et al*[52] thus employed synthetic peptides spanning the entire HDAg sequence in an attempt to determine HDAg-specific helper T-cell recognition of specific antigenic determinants. They studied their fine specificity to identify immunogenic epitopes of HDAg that could be used to generate a vaccine for the prophylaxis and treatment of HDV infection[52]. Furthermore, two studies have identified a low degree of heterogeneity in HDAg which encourage the development of a vaccine using these immunogenic sequences of HDAg[64,65].

The study results of [R Nisini](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nisini%20R%5Bauth%5D), et al, also suggested that HDAg-specific T-cell response in peripheral blood of HDV- infected individual is associated with reduced HDV replication and anti-HD IgM disappearance with the consequent reduced activity of HDV-induced liver disease[52].

A vigorous immune response involving HDAg-specific T-cell response and cytotoxic killing of HDV- infected cells following HDV infection thus, results in both viral clearance and augmented liver damage.

**CELL PROTEOME MODIFICATIONS AND ROLE OF CELLULAR PROTEINS**

Since HDV lacks essential enzymes to carry out its own replication and cell cycle, host cell proteins and components are thus intimately involved in the HDV pathogenesis [9,12].

There are number of cellular proteins identified to date, which interact with HDV RNA and HDAg to accomplish HDV life cycle processes. The interaction of cellular proteins with HDV RNA and HDAg significantly alters cell proteome. Cellular RNA polymerase subunits, helicases, RNA- binding proteins, heterogeneous ribonucleoproteins (hnRNPs), and transcriptional and splicing factors have been known to interact with S-HDAg to facilitate HDV RNA transcription and translation. Host transcription factors interacting with HDAg may remarkably alter cellular gene expression resulting in enhanced cytokines, inflammatory enzymes, growth factors and anti-apoptotic proteins[9] which may suggest severe necro-inflammation, amplified liver damage and a concomitent increased cell survival in HDV infected patients.

Cellular proteins involved in pathways such as regulation of cell metabolism and energy pathways, nucleic acid and protein metabolism, apoptosis and cell growth and maintenance demonstrate a significantly altered expression profile in the presence of HDV components.

**HDV AND CIRRHOSIS**

Progression of liver disease in HDV infection has been demonstrated to be influenced by many factors including mode of infection (*i.e.,* co-infection or super-infection), specific HDAg variants[66] and HDV[67] and HBV[68] genotypes. Super-infection with HDV in chronic HBV is associated with a more severe form of liver disease owing to its exacerbation of pre-existing liver damage due to HBV[69] HBV genotypes have much less convincing evidence of directly influencing liver pathology rather it regulates HDV viral loads which adversely affect disease outcome[70].

Since HDV- infection causes fulminant hepatitis and liver cirrhosis, L-HDAg has shown to stimulate transforming growth factor- β- (TGF-β) and c-Jun-induced signaling cascades which in turn may induce epithelial-mesenchymal transition and fibrogenesis[70,71]. Chronic HDV may thus induce liver cirrhosis by up-regulating the expression of TGF-β. This process is specifically accomplished by the isoprenylation (fernasylation) of L-HDAg[72] Isoprenylation inhibitors, which are yet in their early phase of development, may play a key role in preventing these undesirable outcomes following HDV infection.

**HDV AND HEPATOCELLULAR CARCINOMA**

It is already mentioned that cells infected with HDV appears to have altered gene expression and cellular responses, which is also evident from augmented expression of pro-inflammatory, growth and anti-apoptotic factors. It is thus explanatory that severe liver damage and a concomitant increased hepatic cell survival in HDV-infected patients may lead to HCC.

It is well known that nuclear factor kappa B (NF-κB) dysregulation is associated with inflammation and cancer[73]. L-HDAg has been shown to activate NADPH oxidase-4 which in turn induces oxidative stress. L-HDAg is therefore able to activate the signal transducer and activator of transcription-3 and the NF-κB through the oxidative stress pathway[54]. L-HDAg may also stimulate TNF-α induced NF-κB probably via TNF receptor-associated factor 2 (TRAF2), a protein involved in the early signal transduction events[56]. This may underscore a possible underlying cause of severe necro-inflammation in HDV infection and its progression to HCC. A clinical study has also suggested that HCC in HDV infection may be a secondary effect of the necroinflammation and cirrhosis[74]. In this study decreased liver size was noticed more in cases of HDV HCC compared to HBV mono-infection group where the liver size was normal or increased. HDV patients had lower platelets and larger varices on endoscopy.

Both L-HDAg and S-HDAg have been shown to enhance clusterin gene expression[56] which is found up-regulated in tumor cells and evidently implicated in tumourigenesis[75]. HDAg amplifies the expression of clusterin gene by enhanced acetylation of histone H3 in clusterin gene promoter region. The similar modification has also been observed in several oncogenic viruses associated with the expression of specific proteins, such as the adenovirus protein E1A[76], the simian virus 40T antigen[77] and the E7 protein of the human papilloma virus[72]. An increased histone acetylation and clusterin protein production are associated with increased survival of HDV-infected cells[56].This may reliably be implicated in the development of HCC in HDV- infected patients.

**RELEVANCE OF GENOTYPES**

To date, there are eight genotypes of HDV which have been reported with unexplained variations in their pathogenecity. Furthermore, HDV genotypes have distinct geographical distribution apart from HDV genotype 1 which has been observed universally[47].

The available literature is apparently unable to outline a specific HDV genotype associated with the disease severity in HDV infection as different genotypes are prevalent in different parts of the world and none could be certainly correlated with more severe disease outcome. Any geographic area which reports HDV associated disease severity primarily belongs to the genotypes prevalent in that area. This entity thus requires further research to establish an association between disease severity and different HDV genotype infections. However, [Su](http://www.ncbi.nlm.nih.gov/pubmed?term=Su%20CW%5BAuthor%5D&cauthor=true&cauthor_uid=16697726) *et al*[78] have reported genotype I HDV and older age associated with adverse outcomes in HDV/HBV infection. There are patterns of disease suggesting cytopathic viral illness as was indicated by outbreaks of severe hepatitis in the northern part of South America[79]. These cases were mostly caused by HDV genotype 3.

**CONCLUSION**

Though a global decline in HDV prevalence has now been observed due to better prevention practices, mass awareness and expanded HBV vaccination in industrialized countries, it is still a major health concern in Asia-Pacific region where circumstances favor the spread of hepatitis B and related infections. A scarcity of literature over the HDV life cycle and pathogenesis is clearly evident. Furthermore, severity of HDV-associated liver disease with its adverse outcomes and lack of an efficient treatment regime encourage research into HDV biology. A better understanding of the viral pathogenesis will certainly help the investigating bodies to develop new treatment approaches which would be able to cope with both disease severity and outcome. An innovative approach towards generating a vaccine against HDV is also needed.

**REFERENCES**

1 **Lin JH**, Chang MF, Baker SC, Govindarajan S, Lai MM. Characterization of hepatitis delta antigen: specific binding to hepatitis delta virus RNA. *J Virol* 1990; **64**: 4051-4058 [PMID: 2200884 DOI: 10.1055/s-0032-1323628]

2 **Abbas Z**, Jafri W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. *World J Gastroenterol* 2010; **16**: 554-562 [PMID: 20128022 DOI: 10.3748/wjg.v16.i5.554]

3 **Wang CJ**, Chen PJ, Wu JC, Patel D, Chen DS. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles. *J Virol* 1991; **65**: 6630-6636 [PMID: 1658366]

4 **Lai MM**. Molecular biologic and pathogenetic analysis of hepatitis delta virus. *J Hepatol* 1995; **22**: 127-131 [PMID: 7602064]

5 **Casaca A**, Fardilha M, da Cruz e Silva E, Cunha C. The heterogeneous ribonuclear protein C interacts with the hepatitis delta virus small antigen. *Virol J* 2011; **8**: 358 [PMID: 21774814 DOI: 10.1186/1743-422X-8-358]

6 **Gudima S**, Chang J, Moraleda G, Azvolinsky A, Taylor J. Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA. *J Virol* 2002; **76**: 3709-3719 [PMID: 11907210 DOI: 10.1128/JVI.76.8.3709-3719.2002]

7 **Flores R**, Ruiz-Ruiz S, Serra P. Viroids and hepatitis delta virus. *Semin Liver Dis* 2012; **32**: 201-210 [PMID: 22932968 DOI: 10.1055/s-0032-1323624]

8 **Dastgerdi ES,** Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. *World J Virol* 2012; **1:** 71-78 [PMID: 24175212 DOI: 10.5501/wjv.v1.i3.71]

9 **Greco-Stewart V**, Pelchat M. Interaction of host cellular proteins with components of the hepatitis delta virus. *Viruses* 2010; **2**: 189-212 [PMID: 21994607 DOI: 10.3390/v2010189]

10 **Flores R**, Grubb D, Elleuch A, Nohales MÁ, Delgado S, Gago S. Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme. *RNA Biol* 2011; **8**: 200-206 [PMID: 21358283 DOI: 10.4161/rna.8.2.14238]

11 **Huang CR**, Lo SJ. Evolution and diversity of the human hepatitis d virus genome. *Adv Bioinformatics* 2010; 323654 [PMID: 20204073 DOI: 10.1155/2010/323654]

12 **Sikora D**, Greco-Stewart VS, Miron P, Pelchat M. The hepatitis delta virus RNA genome interacts with eEF1A1, p54(nrb), hnRNP-L, GAPDH and ASF/SF2. *Virology* 2009; **390**: 71-78 [PMID: 19464723 DOI: 10.1016/j.virol.2009.04.022]

13 **Wang JG**, Lemon SM. Hepatitis delta virus antigen forms dimers and multimeric complexes in vivo. *J Virol* 1993; **67**: 446-454 [PMID: 7677957]

14 **Casey JL**. Control of ADAR1 editing of hepatitis delta virus RNAs. *Curr Top Microbiol Immunol* 2012; **353**: 123-143 [PMID: 21732238 DOI: 10.1007/82\_2011\_146]

15 **Sato S**, Cornillez-Ty C, Lazinski DW. By inhibiting replication, the large hepatitis delta antigen can indirectly regulate amber/W editing and its own expression. *J Virol* 2004; **78**: 8120-8134 [PMID: 15254184 DOI: 10.1128/JVI.78.15.8120-8134.2004]

16 **Tseng CH**, Lai MM. Hepatitis delta virus RNA replication. *Viruses* 2009; **1**: 818-831 [PMID: 21994571 DOI: 10.3390/v1030818]

17 **Wang YC**, Huang CR, Chao M, Lo SJ. The C-terminal sequence of the large hepatitis delta antigen is variable but retains the ability to bind clathrin. *Virol J* 2009; **6**: 31 [PMID: 19284884 DOI: 10.1186/1743-422X-6-31]

18 **Li YJ**, Stallcup MR, Lai MM. Hepatitis delta virus antigen is methylated at arginine residues, and methylation regulates subcellular localization and RNA replication. *J Virol* 2004; **78**: 13325-13334 [PMID: 15542683 DOI: 10.1128/JVI.78.23.13325-13334.2004]

19 **Choi SH**, Park KJ, Hwang SB. Large hepatitis delta antigen is phosphorylated at multiple sites and phosphorylation is associated with protein conformational change. *Intervirology* 2002; **45**: 142-149 [PMID: 12403918 DOI: 10.1159/000065867]

20 **Hong SY**, Chen PJ. Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II. *J Virol* 2010; **84**: 1430-1438 [PMID: 19923176 DOI: 10.1128/JVI.02083-09]

21 **Yeh TS**, Lee YH. Assembly of hepatitis delta virus particles: package of multimeric hepatitis delta virus genomic RNA and role of phosphorylation. *Virology* 1998; **249**: 12-20 [PMID: 9740772 DOI: 10.1006/viro.1998.9310]

22 **Mu JJ**, Tsay YG, Juan LJ, Fu TF, Huang WH, Chen DS, Chen PJ. The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis. *Virology* 2004; **319**: 60-70 [PMID: 14967488 DOI: 10.1016/j.virol.2003.10.024]

23 **Tseng CH**, Cheng TS, Shu CY, Jeng KS, Lai MM. Modification of small hepatitis delta virus antigen by SUMO protein. *J Virol* 2010; **84**: 918-927 [PMID: 19889771 DOI: 10.1128/JVI.01034-09]

24 **Lamas Longarela O**, Schmidt TT, Schöneweis K, Romeo R, Wedemeyer H, Urban S, Schulze A. Proteoglycans act as cellular hepatitis delta virus attachment receptors. *PLoS One* 2013; **8**: e58340 [PMID: 23505490 DOI: 10.1371/journal.pone.0058340]

25 **Engelke M**, Mills K, Seitz S, Simon P, Gripon P, Schnölzer M, Urban S. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. *Hepatology* 2006; **43**: 750-760 [PMID: 16557545 DOI: 10.1002/hep.21112]

26 **Yan H**, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *Elife* 2012; **1**: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049]

27 **Huang WH**, Chen YS, Chen PJ. Nucleolar targeting of hepatitis delta antigen abolishes its ability to initiate viral antigenomic RNA replication. *J Virol* 2008; **82**: 692-699 [PMID: 17989182 DOI: 10.1128/JVI.01155-07]

28 **Niro GA**, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. *Curr Infect Dis Rep* 2012; **14**: 9-14 [PMID: 22161240 DOI: 10.1007/s11908-011-0233-5]

29 **Govindarajan S**, Fields HA, Humphrey CD, Margolis HS. Pathologic and ultrastructural changes of acute and chronic delta hepatitis in an experimentally infected chimpanzee. *Am J Pathol* 1986; **122**: 315-322 [PMID: 3511726]

30 **Kamimura T**, Ponzetto A, Bonino F, Feinstone SM, Gerin JL, Purcell RH. Cytoplasmic tubular structures in liver of HBsAg carrier chimpanzees infected with delta agent and comparison with cytoplasmic structures in non-A, non-B hepatitis. *Hepatology* ; **3**: 631-637 [PMID: 6413349 DOI: 10.1002/hep.1840030502]

31 **Canese MG**, Rizzetto M, Novara R, London WT, Purcell RH. Experimental infection of chimpanzees with the HBsAg-associated delta (delta) agent: an ultrastructural study. *J Med Virol* 1984; **13**: 63-72 [PMID: 6420512 DOI: 10.1002/jmv.1890130108]

32 **Ponzetto A**, Hoyer BH, Popper H, Engle R, Purcell RH, Gerin JL. Titration of the infectivity of hepatitis D virus in chimpanzees. *J Infect Dis* 1987; **155**: 72-78 [PMID: 3794405 DOI: 10.1093/infdis/155.1.72]

33 **Cole SM**, Gowans EJ, Macnaughton TB, Hall PD, Burrell CJ. Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. *Hepatology* 1991; **13**: 845-851 [PMID: 1709411 DOI: 10.1002/hep.184013050]

34 **Lefkowitch JH**, Goldstein H, Yatto R, Gerber MA. Cytopathic liver injury in acute delta virus hepatitis. *Gastroenterology* 1987; **92**: 1262-1266 [PMID: 3557018]

35 **Popper H**, Thung SN, Gerber MA, Hadler SC, de Monzon M, Ponzetto A, Anzola E, Rivera D, Mondolfi A, Bracho A. Histologic studies of severe delta agent infection in Venezuelan Indians. *Hepatology* ; **3**: 906-912 [PMID: 6629319 DOI: 10.1002/hep.1840030603]

36 **Casey JL**, Gerin JL. The woodchuck model of HDV infection. *Curr Top Microbiol Immunol* 2006; **307**: 211-225 [PMID: 16903228 DOI: 10.1007/3-540-29802-9\_11]

37 **Casey JL**, Tennant BC, Gerin JL. Genetic changes in hepatitis delta virus from acutely and chronically infected woodchucks. *J Virol* 2006; **80**: 6469-6477 [PMID: 16775334 DOI: 10.1128/JVI.00245-06]

38 **Fiedler M**, Lu M, Siegel F, Whipple J, Roggendorf M. Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. *Vaccine* 2001; **19**: 4618-4626 [PMID: 11535309 DOI: 10.1016/s0264-410x(01)00245-6]

39 **Fiedler M**, Roggendorf M. Vaccination against hepatitis delta virus infection: studies in the woodchuck (Marmota monax) model. *Intervirology* 2001; **44**: 154-161 [PMID: 11509876 DOI: 10.1159/000050042]

40 **Fiedler M**, Roggendorf M. Immunology of HDV infection. *Curr Top Microbiol Immunol* 2006; **307**: 187-209 [PMID: 16903227 DOI: 10.1007/3-540-29802-9\_10]

41 **D'Ugo E**, Canitano A, Catone S, Argentini C, Giuseppetti R, Orobello S, Palmieri G, Rapicetta M. Kinetics of WHV-HDV replication in acute fatal course of woodchuck hepatitis. *Arch Virol* 2008; **153**: 2069-2076 [PMID: 18985276 DOI: 10.1007/s00705-008-0236-1]

42 **Hansson BG**, Riesbeck K, Nordenfelt E, Weiland O. Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response? *Prog Clin Biol Res* 1991; **364**: 421-427 [PMID: 1826956]

43 **Hourioux C**, Sureau C, Poisson F, Brand D, Goudeau A, Roingeard P. Interaction between hepatitis delta virus-encoded proteins and hepatitis B virus envelope protein domains. *J Gen Virol* 1998; **79** (Pt 5): 1115-1119 [PMID: 9603326]

44 **de Sousa BC**, Cunha C. Development of mathematical models for the analysis of hepatitis delta virus viral dynamics. *PLoS One* 2010; **5**: [PMID: 20862328 DOI: 10.1371/journal.pone.0012512]

45 **Williams V**, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, Fagard R, Kremsdorf D, Dény P, Gordien E. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. *J Gen Virol* 2009; **90**: 2759-2767 [PMID: 19625466 DOI: 10.1099/vir.0.011239-0]

46 **Romeo R**, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. *Gastroenterology* 2009; **136**: 1629-1638 [PMID: 19208358 DOI: 10.1053/j.gastro.2009.01.052]

47 **Wedemeyer H**, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 31-40 [PMID: 20051970 DOI: 10.1038/nrgastro.2009.205]

48 **Schaper M**, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, Quer J, Esteban R, Buti M. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. *J Hepatol* 2010; **52**: 658-664 [PMID: 20346531 DOI: 10.1016/j.jhep.2009.10.036]

49 **Hadziyannis SJ.** Hepatitis delta: an overview. In: Rizzetto M, Purcell RH, Gerin JL, and Verme G, eds. Viral Hepatitis and Liver Disease, Turin, Edizioni Minerva Medica, 1997: 283-289.

50 **Pugnale P**, Pazienza V, Guilloux K, Negro F. Hepatitis delta virus inhibits alpha interferon signaling. *Hepatology* 2009; **49**: 398-406 [PMID: 19085955 DOI: 10.1002/hep.22654]

51 **Magrin S**, Craxì A, Carini C, Colombo P, di Blasi F, Spinelli G, Fratazzi C, Messina MC, Antonelli G, Ausiello C. Interleukin-2, interleukin-2 receptor and gamma-interferon synthesis by peripheral blood mononuclear cells in chronic hepatitis delta virus infection. *J Hepatol* 1989; **8**: 358-366 [PMID: 2499617 DOI: 10.1016/0168-8278(89)90035-4]

52 **Nisini R**, Paroli M, Accapezzato D, Bonino F, Rosina F, Santantonio T, Sallusto F, Amoroso A, Houghton M, Barnaba V. Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. *J Virol* 1997; **71**: 2241-2251 [PMID: 9032359]

53 **Franco A**, Barnaba V, Natali P, Balsano C, Musca A, Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. *Hepatology* 1988 449-454 [PMID: 2453428 DOI: 10.1002/hep.1840080302]

54 **Williams V**, Brichler S, Khan E, Chami M, Dény P, Kremsdorf D, Gordien E. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress. *J Viral Hepat* 2012; **19**: 744-753 [PMID: 22967106 DOI: 10.1111/j.1365-2893.2012.01597.x]

55 **Huang IC**, Chien CY, Huang CR, Lo SJ. Induction of hepatitis D virus large antigen translocation to the cytoplasm by hepatitis B virus surface antigens correlates with endoplasmic reticulum stress and NF-kappaB activation. *J Gen Virol* 2006; **87**: 1715-1723 [PMID: 16690938 DOI: 10.1099/vir.0.81718-0]

56 **Liao FT**, Lee YJ, Ko JL, Tsai CC, Tseng CJ, Sheu GT. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. *J Gen Virol* 2009; **90**: 1124-1134 [PMID: 19264665 DOI: 10.1099/vir.0.007211-0]

57 **Löseke S**, Grage-Griebenow E, Heine H, Wagner A, Akira S, Bauer S, Bufe A. In vitro-generated viral double-stranded RNA in contrast to polyinosinic: polycytidylic acid induces interferon-alpha in human plasmacytoid dendritic cells. *Scand J Immunol* 2006; **63**: 264-274 [PMID: 16623926 DOI: 10.1111/j.1365-3083.2006.01736.x]

58 **Larner A**, Reich NC. Interferon signal transduction. *Biotherapy* 1996; **8**: 175-181 [PMID: 8813329 DOI: 10.1007/BF01877202]

59 **Katashiba Y**, Miyamoto R, Hyo A, Shimamoto K, Murakami N, Ogata M, Amakawa R, Inaba M, Nomura S, Fukuhara S, Ito T. Interferon-α and interleukin-12 are induced, respectively, by double-stranded DNA and single-stranded RNA in human myeloid dendritic cells. *Immunology* 2011; **132**: 165-173 [PMID: 20875078 DOI: 10.1111/j.1365-2567.2010.03350.x]

60 **Hartwig D**, Schütte C, Warnecke J, Dorn I, Hennig H, Kirchner H, Schlenke P. The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells. *J Viral Hepat* 2006; **13**: 150-157 [PMID: 16475990]

61 **Babiker ZO**, Hogan C, Ustianowski A, Wilkins E. Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection? *J Med Microbiol* 2012; **61**: 1780-1783 [PMID: 22956751 DOI: 10.1099/jmm.0.046649-0 DOI: 10.1111/j.1365-2893.2005.00663.x]

62 **Kuhla A**, Eipel C, Abshagen K, Siebert N, Menger MD, Vollmar B. Role of the perforin/granzyme cell death pathway in D-Gal/LPS-induced inflammatory liver injury. *Am J Physiol Gastrointest Liver Physiol* 2009; **296**: G1069-G1076 [PMID: 19264954 DOI: 10.1152/ajpgi.90689.2008]

63 **Grabowski J**, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. *Liver Int* 2011; **31**: 1395-1405 [PMID: 21762356 DOI: 10.1111/j.1478-3231.2011.02593.x]

64 **Xia YP**, Chang MF, Wei D, Govindarajan S, Lai MM. Heterogeneity of hepatitis delta antigen. *Virology* 1990; **178**: 331-336 [PMID: 2389557 DOI: 10.1016/0042-6822(90)90415-N]

65 **Imazeki F**, Omata M, Ohto M. Heterogeneity and evolution rates of delta virus RNA sequences. *J Virol* 1990; **64**: 5594-5599 [PMID: 2214027]

66 **Tang JR**, Hantz O, Vitvitski L, Lamelin JP, Parana R, Cova L, Lesbordes JL, Trépo C. Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic. *J Gen Virol* 1993; **74** (Pt 9): 1827-1835 [PMID: 8376962 DOI: 10.1099/0022-1317-74-9-1827]

67 **Wu JC**, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. *Lancet* 1995; **346**: 939-941 [PMID: 7564729 DOI: 10.1016/S0140-6736(95)91558-3]

68 **Kiesslich D**, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, Diaz RS. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. *J Infect Dis* 2009; **199**: 1608-1611 [PMID: 19388852 DOI: 10.1086/598955]

69 **Smedile A**, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. Influence of delta infection on severity of hepatitis B. *Lancet* 1982; **2**: 945-947 [PMID: 6127458 DOI: 10.1016/S0140-6736(82)90156-8]

70 **Choi SH**, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. *Gastroenterology* 2007; **132**: 343-357 [PMID: 17241884 DOI: 10.1053/j.gastro.2006.10.038]

71 **Shih HH**, Sheen IJ, Su CW, Peng WL, Lin LH, Wu JC. Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission. *J Virol* 2012; **86**: 9044-9054 [PMID: 22674995 DOI: 10.1128/JVI.00130-12]

72 **Brehm A**, Nielsen SJ, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. *EMBO J* 1999; **18**: 2449-2458 [PMID: 10228159 DOI: 10.1093/emboj/18.9.2449]

73 **Surh YJ**, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee SS. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. *Mutat Res* 2001; **480-481**: 243-268 [PMID: 11506818]

74 **Abbas Z**, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? *Saudi J Gastroenterol* ; **18**: 18-22 [PMID: 22249087 DOI: 10.4103/1319-3767.91731]

75 **Balantinou E**, Trougakos IP, Chondrogianni N, Margaritis LH, Gonos ES. Transcriptional and posttranslational regulation of clusterin by the two main cellular proteolytic pathways. *Free Radic Biol Med* 2009; **46**: 1267-1274 [PMID: 19353783 DOI: 10.1016/j.freeradbiomed.2009.01.025]

76 **Hamamori Y**, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY, Nakatani Y, Kedes L. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. *Cell* 1999; **96**: 405-413 [PMID: 10025406 DOI: 10.1016/S0092-8674(00)80553-X]

77 **Valls E**, de la Cruz X, Martínez-Balbás MA. The SV40 T antigen modulates CBP histone acetyltransferase activity. *Nucleic Acids Res* 2003; **31**: 3114-3122 [PMID: 12799439 DOI: 10.1093/nar/gkg418]

78 **Su CW**, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. *Gastroenterology* 2006; **130**: 1625-1635 [PMID: 16697726 DOI: 10.1053/j.gastro.2006.01.035]

79 **Nakano T**, Shapiro CN, Hadler SC, Casey JL, Mizokami M, Orito E, Robertson BH. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. *J Gen Virol* 2001; **82**: 2183-2189 [PMID: 11514728]

**P-Reviewers:** Giannecchini S, Kamal SA, Negro F **S-Editor:** Qi Y

 **L-Editor: E-Editor:**

**Figure 1 Hepatitis D virus replication cycle.**

**Figure 2 Depicts hepatitis D virus pathogenesis.**

**Figure 3 Interferon-α signaling and inhibition by hepatitis D virus.** STAT: Signal transducer and activator of transcription; JAK: Janus kinase; ISGF3: INF-stimulated gene factor 3; IRF9: Interferon regulatory factor 9; ISG: INF stimulated genes; ISRE: INF-stimulated response elements; P: Phosphorylated residues.